Agios Pharmaceuticals, Inc. (0HB0.L)
USD 41.74
(-0.05%)
USD 41.74
(-0.05%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -345.46 Million USD | -3.88% |
| 2022 | -213.24 Million USD | -3.02% |
| 2021 | -337.73 Million USD | -13.4% |
| 2020 | -310.53 Million USD | 22.59% |
| 2019 | -394.85 Million USD | -15.31% |
| 2018 | -355.3 Million USD | -13.02% |
| 2017 | -314.36 Million USD | -60.98% |
| 2016 | -195.27 Million USD | -69.28% |
| 2015 | -115.35 Million USD | -118.62% |
| 2014 | -52.76 Million USD | -40.92% |
| 2013 | -37.44 Million USD | -71.63% |
| 2012 | -21.81 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -104.22 Million USD | -14.88% |
| 2024 Q3 | 1 Billion USD | 1061.76% |
| 2024 Q1 | -90.72 Million USD | 13.49% |
| 2023 Q1 | -86.21 Million USD | 9.05% |
| 2023 Q4 | -104.87 Million USD | -5.64% |
| 2023 FY | - USD | -3.88% |
| 2023 Q3 | -99.27 Million USD | -11.25% |
| 2023 Q2 | -89.23 Million USD | -3.51% |
| 2022 Q3 | -86.59 Million USD | 6.75% |
| 2022 FY | - USD | -3.02% |
| 2022 Q4 | -94.79 Million USD | -9.47% |
| 2022 Q2 | -92.86 Million USD | 3.5% |
| 2022 Q1 | -96.23 Million USD | 3.98% |
| 2021 Q1 | -86.32 Million USD | -4.32% |
| 2021 Q2 | -86.52 Million USD | -0.24% |
| 2021 Q3 | -86.57 Million USD | -0.05% |
| 2021 Q4 | -100.21 Million USD | -15.76% |
| 2021 FY | - USD | -13.4% |
| 2020 Q4 | -82.74 Million USD | -6.12% |
| 2020 Q1 | -84.55 Million USD | 18.67% |
| 2020 Q2 | -80.85 Million USD | 4.38% |
| 2020 FY | - USD | 22.59% |
| 2020 Q3 | -77.97 Million USD | 3.56% |
| 2019 FY | - USD | -15.31% |
| 2019 Q4 | -103.96 Million USD | 2.82% |
| 2019 Q2 | -111.82 Million USD | -17.12% |
| 2019 Q3 | -106.97 Million USD | 4.33% |
| 2019 Q1 | -95.47 Million USD | -1.09% |
| 2018 Q2 | -71.21 Million USD | 22.84% |
| 2018 FY | - USD | -13.02% |
| 2018 Q4 | -94.44 Million USD | 3.0% |
| 2018 Q3 | -97.36 Million USD | -36.73% |
| 2018 Q1 | -92.28 Million USD | -4.31% |
| 2017 Q3 | -77.4 Million USD | 6.77% |
| 2017 Q4 | -88.47 Million USD | -14.31% |
| 2017 FY | - USD | -60.98% |
| 2017 Q1 | -65.45 Million USD | -17.54% |
| 2017 Q2 | -83.02 Million USD | -26.84% |
| 2016 Q1 | -22.34 Million USD | 43.78% |
| 2016 Q2 | -55.16 Million USD | -146.85% |
| 2016 Q3 | -62.07 Million USD | -12.53% |
| 2016 FY | - USD | -69.28% |
| 2016 Q4 | -55.68 Million USD | 10.29% |
| 2015 FY | - USD | -118.62% |
| 2015 Q3 | -39.42 Million USD | -25.76% |
| 2015 Q2 | -31.35 Million USD | -549.8% |
| 2015 Q1 | -4.82 Million USD | 81.7% |
| 2015 Q4 | -39.75 Million USD | -0.82% |
| 2014 Q3 | 3.55 Million USD | 119.74% |
| 2014 FY | - USD | -40.92% |
| 2014 Q4 | -26.36 Million USD | -841.84% |
| 2014 Q1 | -11.95 Million USD | -0.42% |
| 2014 Q2 | -18 Million USD | -50.63% |
| 2013 Q4 | -11.9 Million USD | -11.32% |
| 2013 Q1 | -6.69 Million USD | -8.47% |
| 2013 Q2 | -8.15 Million USD | -21.73% |
| 2013 Q3 | -10.69 Million USD | -31.16% |
| 2013 FY | - USD | -71.63% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | -6.17 Million USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Editas Medicine, Inc. | -163.11 Million USD | -111.79% |
| Dynavax Technologies Corporation | 9.66 Million USD | 3674.022% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 451.575% |
| Perrigo Company plc | 646.2 Million USD | 153.461% |
| Illumina, Inc. | -608 Million USD | 43.18% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 103.199% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 23.061% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 96.937% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 110.61% |
| Heron Therapeutics, Inc. | -103.79 Million USD | -232.844% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 107.423% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -826.602% |
| Waters Corporation | 1.02 Billion USD | 133.795% |
| Biogen Inc. | 2.37 Billion USD | 114.534% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -295.147% |
| Evolus, Inc. | -41.81 Million USD | -726.274% |
| Adicet Bio, Inc. | -136.53 Million USD | -153.023% |
| Cara Therapeutics, Inc. | -117.65 Million USD | -193.638% |
| bluebird bio, Inc. | -167.16 Million USD | -106.666% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | -130.144% |
| FibroGen, Inc. | -261.4 Million USD | -32.157% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 120.6% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -677.432% |
| Homology Medicines, Inc. | -47.75 Million USD | -623.396% |
| Geron Corporation | -174.78 Million USD | -97.655% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | -51.439% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | -275.183% |
| Myriad Genetics, Inc. | -67.8 Million USD | -409.535% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -242.631% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 31.769% |
| Zoetis Inc. | 3.68 Billion USD | 109.375% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -583.115% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 129.678% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 211.338% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 107.502% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -857.444% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | -50.196% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | -29.876% |
| Verastem, Inc. | -83.16 Million USD | -315.392% |
| Nektar Therapeutics | -243.1 Million USD | -42.104% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | -53.546% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | -292.641% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 21.341% |
| OPKO Health, Inc. | -65.51 Million USD | -427.299% |
| Exelixis, Inc. | 196.6 Million USD | 275.718% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 183.025% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 418.918% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -519.601% |
| uniQure N.V. | -253.1 Million USD | -36.493% |
| Imunon, Inc. | -20.78 Million USD | -1562.306% |
| Blueprint Medicines Corporation | -474.61 Million USD | 27.211% |
| Insmed Incorporated | -654.73 Million USD | 47.236% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 176.439% |
| TG Therapeutics, Inc. | 26.1 Million USD | 1423.621% |
| Incyte Corporation | 919.42 Million USD | 137.574% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 31.632% |